<DOC>
	<DOCNO>NCT00499330</DOCNO>
	<brief_summary>RATIONALE : Wedge resection segmentectomy may less invasive type surgery lobectomy non-small cell lung cancer may fewer side effect improve recovery . It yet know whether wedge resection segmentectomy effective lobectomy treat stage IA non-small cell lung cancer . PURPOSE : This randomized phase III trial study different type surgery compare well work treat patient stage IA non-small cell lung cancer .</brief_summary>
	<brief_title>Comparison Different Types Surgery Treating Patients With Stage IA Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OUTLINE : This multicenter , randomize study . Patients stratify accord tumor size ( &lt; 1 cm vs 1-1.5 cm v &gt; 1.5-2.0 cm ) ( base maximum dimension determine preoperative CT scan ) , histology ( squamous cell carcinoma v adenocarcinoma v ) , smoke status ( never smoke [ smoke &lt; 100 cigarette lifetime ] v former smoker [ smoke &gt; 100 cigarette AND quit ≥ 1 year ago ] v current smoker [ quit &lt; 1 year ago currently smoke ] ) . Patients randomize 1 2 treatment arm . For information , please see Arms section . Primary Objective : To determine whether DFS sublobar resection ( segmentectomy wedge ) non-inferior lobectomy patient small peripheral ( ≤ 2 cm ) NSCLC . Secondary Objectives : 1 . To determine whether overall survival ( OS ) ( sublobar resection ) non-inferior lobectomy . 2 . To determine rate loco-regional systemic recurrence ( exclusive second primary ) lobar sublobar resection . 3 . To determine difference two arm study pulmonary function determine expiratory flow rate measure 6 month post-operatively . 4 . Imaging Substudy : To explore relationship characteristic primary lung cancer , reveal pre-operative CT PET imaging , outcomes ; determination false-negative rate pre-operative PET scan identification involve hilarand mediastinal lymph node ; assessment utility annual follow-up CT image surgical resection small stage IA NSCLC . After completion study treatment , patient follow every 6 month 2 year annually 5 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Preregistration Eligibility Criteria : 1 . Peripheral lung nodule ≤ 2 cm preoperative CT scan presume lung cancer . The center tumor , see CT , must locate outer third lung either transverse , coronal sagittal plane . Patients pure ground glass opacities pathologically confirm N1 N2 disease eligible . 2 . The tumor location must suitable either lobar sublobar resection ( wedge segment ) . 3 . ECOG performance status 02 . 4 . No prior malignancy within 3 year nonmelanoma skin cancer , superficial bladder cancer , CIS cervix . 5 . No prior chemotherapy radiation therapy malignancy . 6 . No evidence locally advance metastatic disease . 7 . Age ≥ 18 year Intraoperative Randomization Eligibility Criteria : 1 . Histologic confirmation NSCLC ( already obtain ) 2 . Confirmation N0 status frozen section examination . Right side tumor require node level 4 , 7 , 10 sample diagnose negative frozen section . Left side tumor require node level 5 6 , 7 10 sample diagnose negative frozen section . Levels 4 7 node may sample mediastinoscopy , endobronchial ultrasound ( EBUS ) and/or endoscopic ultrasound ( EUS ) , time thoracotomy VATS exploration . Nodes previously sample mediastinoscopy ( EBUS and/or EUS ) either immediately prior within 6 week definitive surgical procedure ( thoracotomy VATS ) need resampled .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>stage IA non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
</DOC>